Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sunil Kumar,Patnaik

第一单位： Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, The Nilgiris, Tamilnadu, India.

作者： Sunil Kumar,Patnaik ^[1] ; Akey Krishna,Swaroop ^[1] ; Mudavath Ravi,Naik ^[2] ; Jubie,Selvaraj ^[1] ; Moola Joghee Nanjan,Chandrasekar ^[1]

作者单位： Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, The Nilgiris, Tamilnadu, India. ^[1] Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, The Nilgiris, Tamilnadu, India. ^[2] School of Life Sciences, JSS Academy of Higher Education & Research(Ooty Campus), Longwood, Mysuru Road, Ooty-643001, Tamilnadu, India. ^[3]

主题词药物重新定位(Drug Repositioning);喹唑啉类(Quinazolines);抗肿瘤药(Antineoplastic Agents);肽类(Peptides)

DOI 10.1055/a-2030-4078

PMID 37068520

发布时间 2023-07-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Drug research

2023年73卷6期

341-348页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2.

Drug research

相似文献

Drug research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2.

Drug research

相似文献

Drug research

相关期刊

检索历史清除